Table 5: Summary of randomized controlled trials evaluating benzodiazepines for the treatmentof insomnia in the elderly
|
Study |
Study quality* |
n |
Mean age
(and SD) |
Length of treatment; d |
Benzodiazepine(s) |
Comparison group(s) |
Summary of results
|
Sleep latency |
Sleep duration |
Nocturnal awakenings |
Sleep quality |
Daytime drowsiness† |
|
Meuleman et al83 |
3 |
14 |
78 (11) |
5 + 2 placebo |
Temazepam, 15 mg |
Placebo, diphenhydramine, 50 mg |
ND
ND |
ND
ND |
ND
ND |
— |
— |
Reeves93 |
4 |
41 |
69.5 |
28 |
Flurazepam, 15 mg Triazolam, 0.25 mg |
Placebo |
ND p < 0.01 |
p < 0.05
p < 0.01 |
ND
p < 0.01 |
ND
p < 0.01 |
— |
Klimm et al96 |
3 |
74 |
73 (1.5) |
14 (7 treatment + 7 placebo) |
Nitrazepam, 5 mg |
Zopiclone, 7.5 mg |
p < 0.01 |
ND |
ND |
ND |
— |
Dement104 |
4 |
46 |
64–86 |
14 (7 treatment + 7 follow-up) |
Flurazepam, 15 mg |
Placebo |
— |
— |
— |
— |
p < 0.05
(flurazepam worse) |
*Quality score based on randomization, double blinding, controlling for baseline differences and follow-up of > 80% of patients; maximum score = 5.
†Daytime drowsiness measured using the Multiple Sleep Latency Test. n = number of subjects; ND = no statistical difference; — = not measured.
|
|